Commonwealth Equity Services
AKBA icon

Commonwealth Equity Services’s Akebia Therapeutics AKBA Stock Holding History

Commonwealth Equity Services’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Hold
12,610
– – ﹤0.01% 4384
2026
Q1 		$17.5K Sell
12,610
-3,114
-20% -$4.28K ﹤0.01% 4261
2025
Q4 		$25.3K Sell
15,724
-8,000
-34% -$16.8K ﹤0.01% 4226
2025
Q3 		$65K Sell
23,724
-622
-3% -$2.07K ﹤0.01% 4137
2025
Q2 		$89K Sell
24,346
-748
-3% -$2.06K ﹤0.01% 4082
2025
Q1 		$48K Buy
25,094
+2,110
+9% +$4.31K ﹤0.01% 4065
2024
Q4 		$44K Buy
22,984
+2,248
+11% +$3.9K ﹤0.01% 3991
2024
Q3 		$27K Hold
20,736
– – ﹤0.01% 3983
2024
Q2 		$21K Sell
20,736
-1,284
-6% -$1.59K ﹤0.01% 3964
2024
Q1 		$40K Buy
22,020
+3,284
+18% +$5.25K ﹤0.01% 3913
2023
Q4 		$23K Buy
+18,736
New +$19.1K ﹤0.01% 3809

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Commonwealth Equity Services's AKBA Position: Q2 2026 in Review

Commonwealth Equity Services held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 12,610 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4384.

Commonwealth Equity Services first reported a position in AKBA in Q4 2023 and has held it in 11 quarters since. The position peaked at $89K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Commonwealth Equity Services held 12,610 shares of Akebia Therapeutics worth $14.4K as of Q2 2026.
  • Commonwealth Equity Services left its Akebia Therapeutics share count unchanged in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4384 holding.
  • Commonwealth Equity Services first reported a position in Akebia Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Commonwealth Equity Services's Akebia Therapeutics position peaked at $89K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.